Chronic renal insufficiency develops in approxi mately 40% of patients with type 1 insulindependent diabetes mellitus. 1 Nephropathy ap pears from 15 to 30 years after the onset of diabetes, is signaled by dipstick-positive proteinuria, and is commonly antedated by diabetic angiopathy, especially diabetic retinopathy. 1 Af ter the appearance of proteinuria, renal function progressively deteriorates, and within 5 years (as indicated by earlier studies 2 ) or 10 years (as cited in a more recent publication 3 ), end-stage diabetic renal disease is reached. During the course of dia betic nephropathy, patients exhibit unremitting proteinuria that frequently is in the nephrotic range, are commonly hypertensive, and are sub ject to a variety of symptoms that arise from such extrarenal complications of diabetes as retinop athy, neuropathy, gastrointestinal autonomic dys function, and coronary insufficiency. 1 " 3 The added burden of renal insufficiency and end-stage renal disease contributes substantially to morbidity and mortality in patients with diabetes mellitus. 4 In an effort to retard the progressive decline in renal function and to delay the onset of endstage renal disease, several therapeutic approaches have been proposed in recent years. Effective control of even mild to moderate hypertension in patients with diabetic nephropathy leads to di minished rates of protein excretion and a decreased rate of loss of renal function. 5 For example, in a study by Parving and associates, 5 reduction of mean arterial pressure from 144/98 mm Hg to 128/84 mm Hg with regimens that consisted of /3-blockers, hydralazine, and diuretics reduced the rate of decline of the glomerular filtration rate from 0.91 to 0.39 mm/min per month and delayed the estimated onset of end-stage renal disease for several years. Converting enzyme inhibitors may exert a protective effect in diabetic nephropathy by mechanisms that are additional to the antihypertensive effect of these agents. Administra tion of captopril for several weeks to patients with diabetes who have advanced nephropathy and heavy proteinuria decreases rates of protein excretion before an effect of captopril on systemic arterial pressure is observed. 6 Treatment with captopril extended over 2 years diminishes rates of decline of renal function from 10.3 to 2.4 ml/ min per year while reducing mean arterial pres sure by only 5 mm Hg. 7 Restriction of dietary protein may also prove to be an effective means of attenuating the loss of renal function in patients with diabetic nephropathy. 8 In seven patients who were maintained on a 40-g high biologic value protein diet and an effective antihypertensive regimen for a 12-month period, glomerular filtration rate, as measured by creatinine clearance, was unchanged whereas pro teinuria was dramatically reduced. 8 Even shortterm restriction of dietary protein for 10 days confers beneficial effects on patients with dia betic glomerular injury, as indicated by an amelioration in the glomerular size selective defect with concomitant reduction in rates of protein excretion. 9 The study by Donadio and associates reported in this issue of the Proceedings (pages 3 to 15) introduces another therapeutic approach to re tard the progression of diabetic nephropathy. These investigators report that in a selected popu lation of 28 patients with diabetes and estab lished nephropathy, maintained for several years on an antiplatelet regimen that consisted of dipyridamole and aspirin, 7 demonstrated appre ciably decreased rates of protein excretion and minimal decline in glomerular filtration rate, whereas the other 21 patients had progressive loss of renal function, including 11 who had endstage renal disease. Although the glomerular fil tration rate before antiplatelet therapy was higher in the patients who failed to exhibit pro gressive loss of renal function, a substantial frac tion of the patients with progressive disease ex hibited pretreatment glomerular filtration rates in the range observed in the stable patients. Basal rates of protein excretion, although tend ing to be lower in the patients responsive to anti-platelet therapy, were not significantly different from those in patients with progressive disease. Thus, the beneficial effects of antiplatelet ther apy in these seven patients are unlikely to be attributable to less functional impairment before the initiation of therapy. Furthermore, such bene ficial effects did not arise from more effective control of systemic hypertension or hyperglycemia because systolic and diastolic blood pres sures as well as mean fasting plasma glucose and hemoglobin Ai c were not significantly different between the responders and the nonresponders. Finally, the patients who failed to have signif icant deterioration in renal function with this therapeutic regimen are also unlikely to be that subset of patients with diabetic nephropathy who exhibit relatively slow rates of decline of renal function. First, after institution of this regimen, these patients demonstrated a reduction in the rate of decline of renal function, as measured by the reciprocal of the serum creatinine plot with time. Such a reduction in the slope of the recip rocal creatinine plots rarely occurs spontane ously in the course of diabetic nephropathy. Sec ond, these seven patients also had a reduction in rates of protein excretion to one-third the basal values when maintained on antiplatelet therapy. Thus, the beneficial effect observed in 25% of the patient population of this study, albeit uncon trolled, cannot be attributed to better preserved pretreatment renal function, stricter glycemic or blood pressure control, or spontaneous reduction in the rate of decline of renal function.
The findings in the short-term studies reported by Donadio and colleagues that the regimen of dipyridamole and aspirin led to increased plate let survival and decreased urinary excretion of thromboxanes, an aggregative prostanoid de rived partly from platelets, suggest that the effi cacy of this regimen may stem from its inhibitory effects on platelet activation. There is a growing consensus that patients with diabetes mellitus have an inordinate activation of platelets, 10 and the attendant release of platelet products exerts damaging effects on vessel walls and microcirculatory beds including those of the kidney. 11 " 13 Banga and Sixma 13 recently summarized the evi dence that suggests that diabetes mellitus is a "hypercoagulable state" with ongoing platelet activation. Platelet survival is decreased, and circulating levels of /J-thromboglobulin and plate let cofactor 4, markers of platelet release, are elevated. Imbalances in coagulation factors and fibrinolytic mechanisms predisposing toward clotting have also been noted. 13 Perhaps the most telling observation is the increased sensitivity of platelets to aggregative stimuli. 14 Platelets harvested from patients with diabetes display increased aggregation after exposure to adenine diphosphate, thrombin, and collagen, and such amplified aggregation can be attenuated by in hibitors of cyclo-oxygenase enzyme activities such as aspirin. The propensity for increased platelet aggregation in patients with diabetes is multifactorial in origin, the factors encompass ing such mechanisms as increased synthesis of thromboxane by platelets, 15 diminished sensitiv ity of platelets to the antiaggregative prostanoid, prostaglandin I 2 , and diminished production of prostaglandin I2 by blood vessel walls. 10, 13, 14 Other abnormalities that suggest perturbed platelet-endothelial interaction and platelet acti vation include elevated levels of von Willebrand factor and fibronectin, 13 proteins that promote platelet adhesion to the vessel wall. Abnormali ties in erythrocytes such as decreased deformability and abnormal rheologic properties have also been implicated in enhanced plateletendothelial interaction. 13, 16 Ongoing platelet activation and aggregation lead to release of platelet contents. These constit uents, summarized in Table 1 , exert a range of mitogenic, inflammatory, and vasoactive effects. The pathogenesis of atherosclerosis serves as a paradigm for the participation of platelets and its products in tissue injury. 17, 18 Of special inter est is the σ-granule protein, platelet-derived growth factor (PDGF), a cationic protein of ap proximately 30,000 molecular weight. This mitogen stimulates the proliferation and migration of smooth muscle cells and fibroblasts and is chemotactic to circulating monocytes. PDGF has been assigned a pivotal role in orchestrating the cellular responses that culminate in the proliferative and degenerative changes seen in the walls of atherosclerotic blood vessels. 18 According to the "response to injury" hypothesis of Ross, 18 endothelial damage and exposure of subendothelial structures incite platelet adherence, activa tion, and the discharge of platelet contents. PDGF stimulates the proliferation of smooth muscle cells and migration of these cells from the media into the intima, promotes intracellular ac cumulation of lipid, and stimulates fibroblastic 82 EDITORIAL Mayo Clin Proc, January 1988, Vol 63 activity and the deposition of collagen. Diabetic macrovascular disease is viewed as essentially a process similar to atherosclerosis in patients without diabetes. 13 Continuous in vivo platelet activation and persistent release of PDGF into the vessel wall, as might be expected in patients with diabetes, may account for the notable pro pensity for macrovascular disease. Additionally, extracts from platelets of patients with diabetes exert greater mitogenic effects on aortic smooth muscle cells in comparison with an identically prepared extract from normal platelets. 19 Thus, greater availability of PDGF in platelets and also enhanced release of PDGF may underlie the in creased incidence of vascular disease in patients with diabetes in comparison with normal subjects.
A similar sequence of events may contribute to the pathogenesis of diabetic nephropathy. Early diabetic kidney lesions consist of basement mem brane thickening and mesangial expansion. Mes angial cells are the glomerular analogue of vas cular smooth muscle cells in that both cellular types are contractile in nature and mesenchymal in origin. Early mesangial expansion in diabetic kidney disease later evolves to diffuse or nodular diabetic glomerulosclerosis. PDGF is a potent mitogen to the glomerular mesangium. PDGF binds to human mesangial cells in culture and stimulates synthesis of DNA and growth of mes angial cells. 20 Heightened platelet activity may thus provide a trophic stimulus to the mesangial area that promotes mesangial expansion and subsequent sclerotic changes. PDGF is also vaso constrictive and induces contraction of mesan gial cells in culture, a property also shared by thromboxanes. 21 Thus, by influencing the con tractile state of the glomerular mesangium, PDGF may decrease the glomerular ultrafiltration coefficient and thus glomerular filtration rate. Finally, PDGF is a cationic protein, exhib iting a positive charge at physiologic pH. Height ened release of PDGF, and other cationic platelet proteins as platelet cofactor 4, may bind to and neutralize a fixed negative charge of the glomer ular filtration barrier; thereby, the selectivity of the glomerular charge is impaired and macromolecules can leak into the urinary space. Thus, the effectiveness of antiplatelet therapy in pre serving glomerular filtration rate and decreasing rates of protein excretion, at least in some subsets of patients with diabetic nephropathy, could con ceivably arise from decreased activation of plate lets and attenuation of the effects of PDGF and other platelet contents on mesangial expansion, mesangial contractility, and glomerular selec tivity. Interestingly, as demonstrated in previous studies by Donadio and colleagues, 22 antiplatelet therapy also preserves glomerular filtration rate in membranoproliferative glomerulonephritis, a disease that, like diabetic glomerulopathy, ex hibits early mesangial expansion.
Platelet activation may also contribute to the microalbuminuria observed in the preclinical phase of diabetic nephropathy. 23 Subjects with diabetes who are dipstick negative on urinalysis but excrete more than 20 //g/min of albumin exhibit so-called microalbuminuria. Thirty such patients were subjected to 16 weeks of treatment with UK-38,485, a specific inhibitor of throm boxane synthetase in platelets and other tissues. Rates of excretion of albumin substantially di minished with such therapy and rebounded to pretreatment levels after discontinuation of use of the drug. No significant change occurred in rates of excretion of albumin in subjects treated with placebo. Reduction in rates of excretion of albu min in conjunction with inhibition of synthesis of thromboxane could not be ascribed to reduction in systemic arterial pressure, nor were differences in glycosylated hemoglobin or mean blood pres sure detected between the two groups. These find ings raise the intriguing possibility that microalbuminuria in patients with diabetes is dependent on increased generation of thromboxane, pos sibly arising from increased platelet activity. The mechanism by which increased synthesis of thromboxane provokes proteinuria is currently unknown, but such a correlation between rates of generation of thromboxane and excretion of pro tein has been observed in multiple models of ex perimental kidney disease, including nephrotoxic serum nephritis, minimal-change nephropathy, the remnant kidney model, and murine lupus nephritis. 24 Because a view is emerging that microalbuminuria might predict that subset of patients with diabetes subsequently destined to have overt diabetic nephropathy, 25 inordinate platelet activity may be at least one determinant for the subsequent manifestation of kidney dis ease in patients with diabetes mellitus.
Alterations in glomerular hemodynamic func tion, per se, are germane to the mechanisms under lying platelet activation in the glomerular microcirculation. Before the onset of clinical diabetic nephropathy, a substantial number of patients with diabetes exhibit elevated glomerular filtra tion rate and renal plasma flow. 26 As reported in studies by Hostetter and associates, 27 animals with experimentally induced diabetes also dem onstrate hyperfiltration and hyperperfusion, both at a whole-kidney and at the single-nephron level. Such augmentation in single-nephron glomerular filtration rate is due to increments in the glo merular capillary hydraulic pressure gradient and single-nephron plasma flow rates. 27 Experi mental maneuvers such as dietary protein re striction 28 and converting enzyme inhibition 29 decrease intraglomerular hypertension in experi mental diabetes and reduce rates of protein ex cretion and glomerular structural lesions. These findings have given rise to the hypothesis that elevation in intraglomerular pressures and plasma flow rates incite glomerular damage, and as glomeruli become obsolescent, adaptive hemo dynamic changes in surviving glomeruli maintain ongoing glomerular damage. 30 Such hemodynamic alterations may trigger platelet activation. Expo sure of the glomerular endothelial surface to sus tained elevations in glomerular pressures and flows in all likelihood provokes endothelial damage with concomitant loss of the nonthrombogenic nature of the endothelium. Platelet adherence, platelet activation, and discharge of platelet granules ensue. Antiplatelet agents may exert their effects by diminishing platelet hypersensitivity to such aggregative surfaces. Additionally, antiplatelet agents may directly influence glomerular hemodynamics. Dipyridamole decreases the filtration fraction in assorted human glomerulopathies, an effect that suggests efferent arteriolar dilatation and reduction in the transcapillary hydraulic pressure gradient. 31 Acute inhibition of cyclooxygenase activity in experimental diabetes leads to reductions in single-nephron plasma flow rates and the glomerular hydraulic pressure gradient, 32 whereas chronic inhibition of prostanoid syn thesis with aspirin prevents the hyperfiltration of early experimental diabetes and diminishes glomerular structural lesions. 33 Thus, antiplatelet therapy may derive efficacy either through direct effects on glomerular hemodynamics or by atten uating the responsivity of platelets to hemodynamically mediated endothelial damage.
Biochemical transformations occurring in the glomerular basement membrane may also pre dispose toward platelet aggregability. Glomer ular basement membranes as well as mem branes in extrarenal sites undergo thickening and chemical alterations before the onset of clin ical nephropathy. 34, 35 One of these biochemical transformations is nonenzymatic glycosylation that involves interaction between carbohydrate and terminal amino groups of proteins or epsilon amino groups of lysine residues. 34, 35 This reaction is influenced by the severity of glycemia and affects proteins with both short and long turn over rates. Such glycosylation of proteins alters both structural and functional properties. 35 Rele vant to platelet behavior is the recent demonstra tion that collagen extracted from the placenta of patients with diabetes displays increased ketoamine-linked glucose, a marker of nonenzy matic glycosylation, and such collagen exhibits increased platelet-aggregating ability. 36 If such properties are also displayed by nonenzymatic glycosylated glomerular proteins, this finding may represent another pathway for platelet acti vation. Thus, biochemical and hemodynamic al terations in the kidneys of patients with diabetes mellitus provide aggregative stimuli to platelets already rendered hyperresponsive by the diabetic milieu.
The importance of the study by Donadio and co-workers is twofold. First, it provides evidence that implicates platelet participation in the pathogenesis of diabetic nephropathy. Second, it intro duces a new therapeutic modality for the man agement of patients with renal disease. This regimen is simple, comparatively inexpensive, and without major side effects; however, data on the effect of this therapy on diabetic retinopathy and the incidence of retinal bleeding are needed. The promising results in this study should serve as a stimulus for a controlled, prospective trial of antiplatelet therapy in diabetic nephropathy. 
